Knight Therapeutics Inc.

Good morning and welcome to the Knight Therapeutics first quarter 2023 results conference call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the conference over to Samara Sakia. Please go ahead.

Thank you, Debbie. Good morning, everyone, and welcome to Knight Therapeutics' first quarter 2023 conference call. I'm joined on today's call with Amal Khoury, our Chief Business Officer, Arvind Uchina, our Chief Financial Officer, and Jeff Martins, our Global VP of Commercial. I'm excited to report an impressive first quarter results, with revenues of over $82 million and 29% growth compared to the same period last year, and record adjusted EBITDA of over $18 million, representing growth of 37% compared to the same period last year. This strong performance is a testament to the hard work and dedication of our team and the continued success of our portfolio across all of our therapeutic areas. In addition to the continued progress of our marketer products, we launched PalbosaClub in Argentina and obtained the regulatory approval in Chile. PalbosaClub is an internally developed branded generic product indicated for the treatment advanced or metastatic breast cancer and is being marketed as Balpacil or Pablacil in our region. We also submitted Tafacitamab or Minjuvi for regulatory approval in Argentina for the treatment of DLBCL. Turning now to the NCIB. During the quarter, we purchased approximately 2.2 million common shares for an aggregate cash consideration of over $10.8 million. Subsequent to the quarter, Knight purchased an additional 1.1 million common shares for aggregate cash consideration of $5.4 million. With this additional purchase, Knight has completed approximately 73% of the July 22 NCIB at an average purchase price of $5.04 per share. I will now turn the call over to Jeff to provide more details on our product results.

Thank you, Samara. In the first quarter of 2023, as Samira mentioned, we have delivered strong revenues of over $82 million, an increase of more than $16 million on a constant currency basis, or 25% versus prior year. We grew across all of our therapeutic areas, mainly due to our innovative and promoted portfolio. Let me start with the performance of our oncology hematology portfolio. During the quarter, revenues, excluding hyperinflation, were $29.1 million, a growth of $5.3 million, or 22% versus the same period last year. Our key promoted brands included Halibut, Vema, and Trollstar, as well as the addition of Akenzio, contributing $7.6 million of incremental revenues, which was partially offset by a reduction in sales of certain mature and branded generic products due to their lifecycle and the entrance of new competitors. As per our infectious disease portfolio, we delivered revenues of $30.8 million, excluding hyperinflation. This portfolio grew by approximately $7.8 million, excluding the impact of the plant transition and termination of our Gilead agreement, effective July 1, 2022. This growth is due to our key promoted brands, the buying patterns of certain customers, as well as deliveries we made in relation to previously announced Amazon contract with the Brazilian Ministry of Health. Now moving to our other specialty portfolio. During the quarter, revenues excluding hyperinflation were $22.7 million. The portfolio grew by approximately $6.2 million, excluding the change in accounting treatment for Exelon. This growth is mainly due to advanced purchases of Exelon in certain countries due to the commercial transition from Novartis to Knight and the purchasing patterns of certain customers. I will now turn the call over to Arvind to provide an update on our financial results.